Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Albireo Pharma is a biotechnology business based in the US. Albireo Pharma shares (ALBO) are listed on the NASDAQ and all prices are listed in US Dollars. Albireo Pharma employs 130 staff and has a trailing 12-month revenue of around $57.4 million.
Finder Award
SoFi Invest
Finder Award
eToro
Robinhood
| Latest market close | $44.59 |
|---|---|
| 52-week range | $16.02 - $44.75 |
| 50-day moving average | $28.12 |
| 200-day moving average | $23.82 |
| Wall St. target price | $43.80 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.70 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $44.59 from 2023-02-06
| 1 week (2023-01-31) | -0.16% |
|---|---|
| 1 month (2023-01-06) | 95.40% |
| 3 months (2022-11-07) | 99.24% |
| 6 months (2022-08-05) | 69.09% |
| 1 year (2022-02-07) | 43.84% |
|---|---|
| 2 years (2021-02-05) | 6.29% |
| 3 years (2020-02-07) | 95.74% |
| 5 years (2018-02-06) | 28.46% |
| Revenue TTM | $57.4 million |
|---|---|
| Gross profit TTM | $39.2 million |
| Return on assets TTM | -24.94% |
| Return on equity TTM | -93.08% |
| Profit margin | -228.51% |
| Book value | $4.84 |
| Market capitalisation | $926.9 million |
TTM: trailing 12 months
We're not expecting Albireo Pharma to pay a dividend over the next 12 months.
Albireo Pharma's shares were split on a 1:30 basis on 3 November 2016. So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Albireo Pharma shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for Albireo Pharma shares which in turn could have impacted Albireo Pharma's share price.
Over the last 12 months, Albireo Pharma's shares have ranged in value from as little as $16.02 up to $44.75. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Albireo Pharma's is 0.7119. This would suggest that Albireo Pharma's shares are less volatile than average (for this exchange).
Albireo Pharma, Inc. , a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases. The company has a license agreement with EA Pharma Co. , Ltd. for the development and commercialization of elobixibat.
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.